Status:
COMPLETED
Special Survey for Long Term Application
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Genetic Disorder
Achondroplasia
Eligibility:
All Genders
1-15 years
Brief Summary
This study is conducted in Japan. The aim of this study is to assess the incidence rate of adverse drug reactions (ADRs) when using somatropin (Norditropin®) for treatment of for achondroplasia withou...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Achondroplasia without epiphyseal line closure
Exclusion
Key Trial Info
Start Date :
May 1 1997
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 31 2007
Estimated Enrollment :
395 Patients enrolled
Trial Details
Trial ID
NCT01516229
Start Date
May 1 1997
End Date
March 31 2007
Last Update
February 27 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Tokyo, Japan, 1000005
2
Novo Nordisk Investigational Site
Tokyo, Japan, 103